Of the 6 ligands identified from binding studies, cyanopindolol, carpindolol, and bucindolol had higher β1‐AR partial agonism than labetolol, suggesting more potential long‐term cardiovascular risk (regardless of their effects in cancer). The gene discussed is ADRB1; the disease is cancer.